5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | BUY | BUY | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 0.25▲ | 0.25▲ | 0.25▲ | 0.25▼ | 0.26▼ |
MA10 | 0.25▲ | 0.25▲ | 0.25▲ | 0.25▼ | 0.29▼ |
MA20 | 0.25▲ | 0.25▲ | 0.25▲ | 0.26▼ | 0.30▼ |
MA50 | 0.25▲ | 0.25▲ | 0.25▲ | 0.29▼ | 0.73▼ |
MA100 | 0.25▲ | 0.26▼ | 0.27▼ | 0.32▼ | 1.29▼ |
MA200 | 0.27▼ | 0.30▼ | 0.30▼ | 0.56▼ | N/A |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.000▼ | 0.000▲ | 0.001▲ | -0.001▼ | 0.029▲ |
RSI | 53.163▲ | 52.626▲ | 51.768▲ | 38.906▼ | 37.591▼ |
STOCH | 68.287 | 44.074 | 39.807 | 32.909 | 20.124 |
WILL %R | -28.125 | -48.889 | -47.826 | -77.716▼ | -93.541▼ |
CCI | 55.014 | 35.190 | 49.686 | -71.760 | -111.120▼ |
▲ GAP | $BIAF Open Gap Up %2 | Set Alert |
Tuesday, May 20, 2025 10:26 AM
BIAF’s Earnings Summary For the first quarter of 2025, bioAffinity reported revenues of $1.9 million, down 22.9% from $2.4 million in the year-ago period. The decline was primarily due to ...
|
Tuesday, May 20, 2025 09:15 AM
BIAF Stock Rises Post Q1 Earnings Despite Revenue Decline May 20, 2025 — 12:15 pm EDT Written by Zacks Equity Research for Zacks -> ...
|
Tuesday, May 20, 2025 05:16 AM
bioAffinity's first-quarter 2025 results show CyPath Lung sales growth and cost cuts despite a drop in total revenues and a wider quarterly net loss.
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
29/08/25 | 0.25 | 0.2529 | 0.241 | 0.2421 | 168,532 |
28/08/25 | 0.25 | 0.2579 | 0.2412 | 0.2446 | 257,679 |
27/08/25 | 0.2455 | 0.26 | 0.2455 | 0.248 | 167,081 |
26/08/25 | 0.25 | 0.2555 | 0.2456 | 0.2522 | 171,826 |
25/08/25 | 0.2487 | 0.2591 | 0.246 | 0.2492 | 186,771 |
22/08/25 | 0.242 | 0.267 | 0.242 | 0.2536 | 223,089 |
21/08/25 | 0.2506 | 0.2506 | 0.24 | 0.249 | 193,407 |
20/08/25 | 0.2595 | 0.2614 | 0.2415 | 0.2492 | 481,983 |
19/08/25 | 0.241 | 0.2781 | 0.2397 | 0.2672 | 1,314,521 |
18/08/25 | 0.2391 | 0.2577 | 0.2321 | 0.245 | 509,750 |
|
|
||||
|
|
||||
|
|